Affiliation:
1. Research Institute for Complex Issues of Cardiovascular Diseases
Abstract
Highlights. The review synthesizes the results of clinical studies on the use of sartans. This topic is highly relevant due to the antihypertensive, metabolic and organ-protective effect of sartans, which can positively affect the course of coronary atherosclerosis.Abstract. Angiotensin II receptor blockers (sartans) are widely used to treat cardiovascular diseases. This class of drugs has antihypertensive and metabolic effects and organ-protective capabilities. Currently, sartans are of high interest due to their pleiotropic effect: improved lipid metabolism, antidiabetogenic action, nephroprotection, and, as a result, reduced total cardiovascular risk. The article presents an overview of clinical data on the use of sartans in patients with ischemic heart disease, the mechanisms of organ-protective effects and prospects of using this class of drugs for total cardiovascular risk reduction. The following data sources were used: e-Library, ClinicalTrials.gov, PubMed, trialbulletin.com, smartpatients.com, BioPortfolio.com.
Subject
Cardiology and Cardiovascular Medicine,Critical Care and Intensive Care Medicine,Rehabilitation,Emergency Medicine,Surgery
Reference50 articles.
1. Kareva E.N. The evolution of sartans, or are all sartans the same? Klinicheskaja farmakologija i terapija. 2016; 25(3): 11-21. (In Russian)
2. Martynyuk T.V., Chazova I.E. The role of the angiotensin receptors blocker telmisartan in the treatment of arterial hypertension. Kardiologicheskij Vestnik. 2017; (3): 76-82. (In Russian)
3. Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U., Fyhrquist F., Ibsen H., Kristiansson K., Lederballe-Pedersen O., Lindholm L.H., Nieminen M.S., Omvik P., Oparil S., Wedel H.; LIFE Study Group. et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002; 359(9311): 995-1003. doi:10.1016/S0140-6736(02)08089-3.
4. Montalescot G., Sechtem U., Achenbach S., Andreotti F., Arden C., Budaj A. et al. 2013 ESC guidelines on the management of stable coronary artery. Eur Heart J. 2013; 34: 2949-3003. doi: 10.1093/eurheartj/eht296.
5. Kosarev V.V., Babanov S.A. Features of the clinical pharmacology of sartans. Russian Medical Journal. 2012; 20(28): 1427-1432. (In Russian)
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献